Evidence map›Paper›PMID 40008176›Full record

ArticleERJ open research2025

Contrasting the clinical and biological characteristics of young and old COPD patients.

Marc Vila, Alvar Agustí, Jørgen Vestbo, Bartolome Celli, Borja G Cosio, Edwin K Silverman, Oriol Sibila, Joan Ramon Badía, Per Bakke, Ruth Tal-Singer and 2 more

Abstract read
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marc VilaEquip d'Atenció Primària Vic (EAPVIC), Universitat de Vic-Universitat Central de Catalunya, Vic, Spain.
Alvar AgustíRespiratory Institute, Hospital Clinic, Barcelona, Spain.ORCID https://orcid.org/0000-0003-3271-3788
Jørgen VestboDivision of Infection, Immunity, and Respiratory Medicine, The University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0001-6355-6362
Bartolome CelliHarvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-7266-8371
Borja G CosioHospital Universitario Son Espases-IdISBa, Palma de Mallorca, Spain.ORCID https://orcid.org/0000-0002-6388-8209
Edwin K SilvermanChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Oriol SibilaRespiratory Institute, Hospital Clinic, Barcelona, Spain.
Joan Ramon BadíaRespiratory Institute, Hospital Clinic, Barcelona, Spain.
Per BakkeDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Ruth Tal-SingerGlobal Allergy and Airways Patient Platform, Vienna, Austria.ORCID https://orcid.org/0000-0002-5275-8062
William MacNeeUniversity of Edinburgh Medical School, Edinburgh, UK.
Rosa FanerUniversity of Barcelona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The ECLIPSE study was a large, international, prospective, controlled, observational study that included COPD patients (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 2-4), as well as smoking and non-smoking participants with normal spirometry, aged 40-75 years, who were followed-up regularly for 3 years. Here we sought to contrast the clinical and biological characteristics of young COPD Methods: We compared 106 young (<50 years) and 488 old (>70 years) COPD patients, as well as 119 young smokers and 92 nonsmoker controls (<50 years) with normal spirometry. Results: Young COPD patients: 1) were more symptomatic than young controls, often reported a family history of chronic bronchitis, emphysema and asthma, as well as a personal history of asthma and bronchitis, and suffered from a similar disease burden to older patients; 2) were at higher risk of substantial forced expiratory volume in 1 s decline over time; and 3) had reduced serum levels of CC16 (a lung-derived anti-inflammatory protein that relates to lung damage) and, at the same time, reduced pro-inflammatory markers compared to older COPD patients. Conclusions: Young COPD patients suffer from significant disease burden, display an altered biomarker and disease progression profile reflected by an accelerated risk of lung function decline highlighting the need for early life diagnosis, prevention approaches and treatment.

Identifiers

PMID40008176
PMCPMC11849125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.